<DOC>
	<DOCNO>NCT02978261</DOCNO>
	<brief_summary>This phase I , open-label , dose-escalation study conduct determine maximum tolerate dose ( MTD ) , recommend phase II dose ( RP2D ) , dose-limiting toxicity ( DLTs ) , pharmacokinetics ( PK ) profile , preliminary antitumor activity single multiple dos PLB1001 Patients PTPRZ1-MET fusion gene positive recurrent high-grade Gliomas .</brief_summary>
	<brief_title>Study c-Met Inhibitor PLB1001 Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas</brief_title>
	<detailed_description>This Phase I , open-label study PLB1001 administer orally patient PTPRZ1-MET fusion gene positive recurrent high-grade Gliomas . The aim dose-escalation study estimate MTD identify dose-limiting toxicity ( DLT ) recommend phase II dose ( RP2D ) PLB1001 single agent well determine PK/PD profile . Aprox . 20 patient enrol study . PLB1001 potent selective c-Met inhibitor . PLB1001 act cancer block abnormal cMET-mediated signaling ( include PTPRZ1-MET fusion gene ) , lead profound tumor growth inhibition xenograft PTPRZ1-MET fusion gene positive glioblastoma tumor .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>Signed Informed Consent Form Age≥18 year Histologically cytologically confirm recurrent highgrade glioma concurrent adjuvant chemoradiotherapy Prior treatment temozolomide Must evidence PTPRZ1MET fusion gene positivity result molecular prescreening evaluation At least one measurable lesion per RANO No evidence recent haemorrhage baseline MRI brain Stable decrease dose corticosteroid within 5 day prior first dose Major surgery within 4 week prior first dose PLB1001 Previous anticancer investigational agent within 4 week first dose PLB1001 . If previous treatment monoclonal antibody , treatment must discontinue least 6 week first dose PLB1001 Pregnant nursing woman Involved clinical trial &lt; 30 day prior first dose Prior therapy gamma knife focal highdose radiotherapy allow , patient must subsequent histologic documentation recurrence , unless recurrence new lesion outside irradiated field Karnofsky performance status ≥ 50 % Previous current treatment cMet inhibitor HGFtargeting therapy The subject unable undergo MRI scan ( e.g . pacemaker ) Clinically significant , uncontrolled heart diseases： Unstable angina ; History document congestive heart failure ( New York Heart Association functional classification &gt; II ) ; Uncontrolled hypertension define Systolic Blood Pressure ( SBP ) ≥ 145 mm Hg and/or Diastolic Blood Pressure ( DBP ) ≥85 mm Hg ; Arrhythmias . Active peptic ulcer disease gastritis Adverse event prior anticancer therapy resolve Grade ≤ 1 , except alopecia Major surgery within 4 week prior first dose PLB1001 Previous anticancer investigational agent within 4 week first dose PLB1001 . If previous treatment monoclonal antibody , treatment must discontinue least 6 week first dose PLB1001 Pregnant nursing woman Involved clinical trial &lt; 30 day prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>